NERV - Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions.
As of Aug 28, 2026: spot at $4.91, ATM IV 54.4%, max pain $5.00, net GEX -$2.9K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $253.0M
- Beta
- -0.11
- 52-Week Range
- 1.93-12.46
- CEO
- Remy Luthringer
- Employees
- 7
- IPO Date
- Jul 1, 2014
- Exchange
- NASDAQ
What NERV Looks Like to Options Traders Today
IV rank of 11.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); negative net gamma exposure (-$2.9K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves.
What This Page Covers
The NERV overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked NERV overview questions
- What is NERV?
- NERV is the ticker symbol for Minerva Neurosciences, Inc., a listed security. Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Listed on NASDAQ. NERV is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the NERV options snapshot look like today?
- As of Aug 28, 2026, the NERV options snapshot shows spot at $4.91, ATM IV 54.4%, IV rank 11.1%, max pain $5.00, net GEX -$2.9K, expected move 15.60%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are NERV's key statistics?
- Minerva Neurosciences, Inc. (NERV) carries a market capitalization of $253.0M, beta of -0.11 relative to the broader market, 52-week range of 1.93-12.46. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does NERV belong to?
- Minerva Neurosciences, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare NERV's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the NERV data on this page?
- The options snapshot above is dated Aug 28, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).